By Carl O’Donnell and Manas Mishra (Reuters) – Aimmune Therapuetics Inc said its peanut allergy drug, whose launch had been paused because of coronavirus lockdowns, is again being administered to patients as allergy specialists reopen, the drugmaker’s executives told Reuters on Thursday. Patient uptake of Palforzia could accelerate further later i…
The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly’s drug to treat a type of skin disease due to certain findings…
3 in 4 parents are concerned about the impact of air quality problems on their child’s health. 2 in 3 parents report poor or unhealthy…
But they acknowledge that taking the only shelf-accessible product off the market raises issues
Nestlé announced Monday the divestment of its peanut allergy treatment business Palforzia (peanut allergen powder-dnfp) to Stallergenes Greer for an undisclosed sum. Nestlé kicked off…
Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.
For patients who have undiagnosed cancer, a months-long delay due to new prior authorization requirements for colonoscopies could be disastrous.
Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published…
The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.
